Loading
Life sciences · Journal article
Chemmedchem · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Pim‐1, a carcinogenic threonine and serine kinase, inhibits apoptosis and advances the cell cycle. It is overexpressed in several human cancers. The proviral integration site of Moloney murine leukemia virus 1 is Pim‐1. Previous studies have shown that the Pim‐1 30‐UTR regulates the stability of Pim‐1 mRNA. Threonine and serine are identified as the proto‐oncogene Pim‐1 kinase. Pim‐1 mediates numerous biological processes, including apoptosis, cell division, proliferation, and cancer. Pim‐1‐mediated anticancer activity has been reported in several analogs of thiazole/ bis ‐thiazole, tetrazine, thiophenes, quinoline, pyrazolopyrimidine, 3‐cyanopyridine, thiazolidine‐2,4‐dione, thieno[2,3‐ b ]pyridine, triazolo[4,3‐ b ]pyridazine, pyrazolo[1,5‐ a ]pyrimidines, and pyrazolo[3,4‐ b ]pyridine derivatives. Additionally, flavonoids and amino alcohol compounds that constitute Pim‐1‐mediated cancer therapy have also been identified thus far. Many compounds with Pim‐1‐mediated cytotoxicity have been discovered up to this point, and scientists are currently concentrating on bringing novel compounds with anticancer potential to the market.